SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%
News
MNK
--
0.00%
--
Were Hedge Funds Right About Ditching Mallinckrodt Public Limited Company (MNK)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 3h ago
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Zacks · 10h ago
Mallinckrodt shares are trading lower on continued momentum from yesterday after the company announced its possible that it and most of its subsidiaries could file for Chapter 11 reorganization in the near term.
Benzinga · 11h ago
DOJ wants as much as $18.1B from Purdue Pharma for opioid epidemic
The U.S. Department of Justice is demanding OxyContin maker Purdue Pharma pay as much as $18.1B in penalties as part of its bankruptcy reorganization plan,
seekingalpha · 12h ago
Mallinckrodt Stock Sinks After the Drugmaker Said It Might File for Bankruptcy
Its headline second-quarter earnings results were better than expected. But it is struggling with more than 2,500 lawsuits over its opioid sales and other issues.
Barrons.com · 1d ago
Mallinckrodt down 20% on talks of possible bankruptcy filing
Despite beating Q2 consensus, Mallinckrodt (MNK) is down 20% premarket. Due to pressures from the Acthar Gel Medicaid matter, the ongoing opioid litigation
seekingalpha · 1d ago
Coronavirus update: U.S. case tally at 4.74 million as New Jersey, Massachusetts and Connecticut see infections climb again
marketwatch.com · 1d ago
Mallinckrodt EPS beats by $0.55, beats on revenue
Mallinckrodt (NYSE:MNK): Q2 Non-GAAP EPS of $1.89 beats by $0.55; GAAP EPS of -$11.04 misses by $11.10. Revenue of $700.9M (-14.9% Y/Y) beats by $70.71M. S
seekingalpha · 1d ago
Drugmaker Mallinckrodt Weighs Bankruptcy to Manage Litigation
bloomberg.com · 1d ago
Mallinckrodt shares are trading lower after the company announced its possible that it and most of its subsidiaries could file for Chapter 11 reorganization in the near term.
Benzinga · 1d ago
Mallinckrodt (MNK) Beats Q2 Earnings and Revenue Estimates
Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Mallinckrodt stock plunges after talks regarding possible bankruptcy filing, offsetting adjusted profit beat
Shares of Mallinckrodt PLC plunged 25% in premrket trading Tuesday, reversing an earlier gain, after the specialty pharmaceutical company swung to a large net loss, but reported an adjusted profit that beat expectations, while disclosing talks with creditors
MarketWatch · 1d ago
Mallinckrodt Says Possible That Co and Most of Its Subsidiaries Could File for Chapter 11 Reorganization in the Near Term
Benzinga · 1d ago
Mallinckrodt Q2 Adj. EPS $1.89 Beats $1.35 Estimate, Adj. Sales $700.90M Beat $635.33M Estimate
Mallinckrodt (NYSE:MNK) reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.35 by 40 percent. This is a 25.3 percent decrease over earnings of $2.53 per share from the same
Benzinga · 1d ago
Mallinckrodt plc Reports Earnings for the Second Quarter 2020 and Highlights Pipeline Advancements
Second quarter net sales of $166.5 million net of the retrospective one-time Acthar
PR Newswire · 1d ago
Mallinckrodt in talks with creditors and litigation claimants regarding possibility of bankruptcy filing
marketwatch.com · 1d ago
Mallinckrodt Q2 2020 Earnings Preview
Mallinckrodt (NYSE:MNK) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. The consensus EPS Estimate is $1.34 (-47.0
seekingalpha · 2d ago
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 6d ago
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 6d ago
LYG, BBVA among premarket losers
Seeking Alpha · 6d ago